Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Gary, Acton"'
Autor:
John N. Allan, Javier Pinilla-Ibarz, Douglas E. Gladstone, Krish Patel, Jeff P. Sharman, William G. Wierda, Michael Y. Choi, Susan M. O’Brien, Mazyar Shadman, Matthew S. Davids, John M. Pagel, Habte A. Yimer, Renee Ward, Gary Acton, Pietro Taverna, Daniel L. Combs, Judith A. Fox, Richard R. Furman, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 107, Iss 4 (2021)
Externí odkaz:
https://doaj.org/article/2b83f0254400461d8896d202887eadb7
Autor:
Laura Tornatore, Daria Capece, Daniel D'Andrea, Federica Begalli, Daniela Verzella, Jason Bennett, Gary Acton, Elizabeth A. Campbell, James Kelly, Michael Tarbit, Nigel Adams, Selina Bannoo, Antonio Leonardi, Annamaria Sandomenico, Domenico Raimondo, Menotti Ruvo, Angela Chambery, Metod Oblak, Magda J. Al-Obaidi, Richard S. Kaczmarski, Ian Gabriel, Heather E. Oakervee, Martin F. Kaiser, Ashutosh Wechalekar, Reuben Benjamin, Jane F. Apperley, Holger W. Auner, Guido Franzoso
Publikováno v:
Toxicology Reports, Vol 6, Iss , Pp 369-379 (2019)
Aberrant NF-κB activity drives oncogenesis and cell survival in multiple myeloma (MM) and many other cancers. However, despite an aggressive effort by the pharmaceutical industry over the past 30 years, no specific IκBα kinase (IKK)β/NF-κB inhib
Externí odkaz:
https://doaj.org/article/2bef177c9ad24c388d8e263481c9368e
Autor:
Darren Hargrave, Murray Yule, Melanie J. Griffin, Alan V. Boddy, John F. Lyons, Ana Rodriguez, Victoria Lock, Shamim Kazmi-Stokes, Philip Ross, Gary Acton, Sarah E.R. Halford, Guy Makin, Quentin Campbell-Hewson, Martin Elliott, Bruce Morland, Andrew D.J. Pearson, Lynley V. Marshall, Lucas Moreno
Supplementary Figure 1. Examples of changes observed in M30/M65 profiles as a function of dosing of AT9283 in two selected patients. Pt. 58/032 from cohort 4 (14.5 mg/m2/day) and Pt. 31/030 from cohort 6 (23 mg/m2/day).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecad42031facf935942fc7b688af840e
https://doi.org/10.1158/1078-0432.22460577.v1
https://doi.org/10.1158/1078-0432.22460577.v1
Autor:
Darren Hargrave, Murray Yule, Melanie J. Griffin, Alan V. Boddy, John F. Lyons, Ana Rodriguez, Victoria Lock, Shamim Kazmi-Stokes, Philip Ross, Gary Acton, Sarah E.R. Halford, Guy Makin, Quentin Campbell-Hewson, Martin Elliott, Bruce Morland, Andrew D.J. Pearson, Lynley V. Marshall, Lucas Moreno
Supplementary Table 1. Summary of pharmacodynamic changes observed in paired skin punch biopsies. Skin punch biopsies were optional until a dose limiting toxicity was found (11.5 mg/m2/day) when they were mandated. Inhibition of pHH3 (substrate for A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::950e620f9c4ac0b51c81c065ed2a89b6
https://doi.org/10.1158/1078-0432.22460574
https://doi.org/10.1158/1078-0432.22460574
Autor:
Darren Hargrave, Murray Yule, Melanie J. Griffin, Alan V. Boddy, John F. Lyons, Ana Rodriguez, Victoria Lock, Shamim Kazmi-Stokes, Philip Ross, Gary Acton, Sarah E.R. Halford, Guy Makin, Quentin Campbell-Hewson, Martin Elliott, Bruce Morland, Andrew D.J. Pearson, Lynley V. Marshall, Lucas Moreno
Purpose: A phase I trial of AT9283 (a multitargeted inhibitor of Aurora kinases A and B) was conducted in children and adolescents with solid tumors, to identify maximum-tolerated dose (MTD), safety, efficacy, pharmacokinetics, and pharmacodynamic (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ebdd8f39fe18202f828f43bd11730ed
https://doi.org/10.1158/1078-0432.c.6524535.v1
https://doi.org/10.1158/1078-0432.c.6524535.v1
Autor:
Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael D. Craig, Norbert Vey, Stephen A. Strickland, Gary J. Schiller, Elias Jabbour, Arnaud Pigneux, Heinz-August Horst, Christian Récher, Virginia M. Klimek, Jorge E. Cortes, Angelo-Michele Carella, Miklos Egyed, Utz Krug, Judith A. Fox, Adam R. Craig, Renee Ward, Jennifer A. Smith, Gary Acton, Hagop M. Kantarjian, Robert K. Stuart
Publikováno v:
Haematologica, Vol 103, Iss 11 (2018)
Externí odkaz:
https://doaj.org/article/5384cf102cb7445faf426cdc5236f71f
Publikováno v:
Goldschmidt2022 abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0c58d21c14cca882342b5009e52715f
https://doi.org/10.46427/gold2022.8859
https://doi.org/10.46427/gold2022.8859
Autor:
J Thomas, Terry Jones, Pandurangan Vijayanand, James McCaul, Rabindra P. Singh, Allan Hackshaw, Lindsey Chudley, Gareth O. Thomas, Monalisa Mondal, William R. Wilson, Danielle Jeffrey, F. E. Kelly, Christian H. Ottensmeier, Nicola Dobbs, Emma King, Wood Oliver, Yingcong Li, Simon Eschweiler, Louisa Essame, Paul M. Loadman, Joseph E. Davies, Elena Lopez-Guadamillas, Klaus Okkenhaug, Ferhat Ay, Adrian von Witzleben, Joseph J. Sacco, Gavin Halbert, Andrew Schache, Gary Acton, Peter A. Brennan, Claire Paterson, Katy J. McCann, Ciro Ramirez Suastegui, Richard Shaw, Hayley Simon, Alice Wang, Bart Vanhaesebroeck, Greg Friberg
Phosphoinositide 3-kinase δ (PI3Kδ) plays a key role in lymphocytes and inhibitors targeting this PI3K have been approved for hematological malignancies. While studies in hematological and solid tumor models in mice have demonstrated that PI3Kδ in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82bf11ce21becfb1401ec9bfd0cefbc8
https://doi.org/10.21203/rs.3.rs-337290/v1
https://doi.org/10.21203/rs.3.rs-337290/v1
Publikováno v:
Physics of the Earth and Planetary Interiors. 328:106864
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cbe16f16bdbe3a952c782f96b2c5aaf
https://doi.org/10.1016/j.pepi.2022.106864
https://doi.org/10.1016/j.pepi.2022.106864
Autor:
Hamid Sayar, Heinz A. Horst, Stephen A. Strickland, Arnaud Pigneux, Gary J. Schiller, Michael Craig, Robert K. Stuart, Miklos Egyed, Renee Ward, Elias Jabbour, Jennifer A. Smith, Hagop M. Kantarjian, Jorge E. Cortes, Gary Acton, Utz Krug, Angelo Michele Carella, Farhad Ravandi, Ellen K. Ritchie, Judith A. Fox, Adam R. Craig, Norbert Vey, Jeffrey E. Lancet, Virginia M. Klimek, Christian Recher
Publikováno v:
Haematologica. 103:e514-e518
Refractory/early relapsed (Ref/eRel) acute myeloid leukemia (AML) in patients ≥60 years old is the most important unmet medical need in the salvage setting, where outcomes are exceptionally poor and no standard of care exists.[1][1] Vosaroxin is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1622ba9588a5b6b17e3372ecbfbf023
https://doi.org/10.3324/haematol.2018.191361
https://doi.org/10.3324/haematol.2018.191361